Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Additional Chemotherapy Administered Directly Into the Liver Using a Chemo Pump in Patients With Bile Duct Cancer Inside the Liver Treatable by Surgery (PUMP IV)

21 de setembro de 2026 atualizado por: Bas Groot Koerkamp, MD, PhD, Erasmus Medical Center

Prevenção da recorrência hepática após hepatectomia parcial para colangiocarcinoma intra -hepático usando quimioterapia adjuvante da bomba de infusão arterial hepática - ensaio IV da bomba iv

The goal of this clinical trial is to learn if additional chemotherapy by means of a chemo pump can prevent return of disease in adult patients with bile duct cancer in the liver that can be treated with surgery. The main questions it aims to answer are:

  • Does addition of chemotherapy by means of a chemo pump lead to less return of disease within the liver two years after surgery?
  • Does addition of chemotherapy by means of a chemo pump lead to longer survival of patients?
  • Does addition of chemotherapy by means of a chemo pump lead to an increase in quality of life?

Participants will receive an implanted chemo pump, through which additional chemotherapy will be given to the liver in addition to surgery.

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Estimado)

40

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

    • South Holland
      • Rotterdam, South Holland, Holanda, 3015GD
        • Recrutamento
        • Erasmus Medical Center
        • Contato:
        • Contato:
        • Investigador principal:
          • Bas Groot Koerkamp, MD, PhD

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • 18 years or older
  • ECOG or WHO performance status 0 or 1
  • Diagnosis of resectable iCCA on imaging. No histological confirmation is needed before surgery, according to standard of care.
  • Patient is able to undergo a laparotomy.
  • Positioning of a catheter for HAIP chemotherapy is technically feasible based on a CT-scan with early arterial phase with 1mm cuts. The default site for the catheter insertion is the GDA. Accessory or aberrant hepatic arteries are no contraindication for catheter placement.
  • Adequate bone marrow, liver, and renal function before inclusion (values may be max. 30 days old)
  • Absolute neutrophil count (ANC) ≥ 1.5 x 10^ 9/L
  • White blood cell count (WBC) ≥ 2.5 x 10^9/L
  • Platelets ≥ 100 x 10^9/L
  • Glomerular filtration rate (GFR) ≥ 30 ml/min
  • Haemoglobin (Hb) ≥ 5.5 mmol/L
  • Total bilirubin ≤ 25 µmol/L
  • Written informed consent must be given according to ICH/good clinical practice (GCP), and national/local regulations.

Exclusion Criteria:

  • Presence of extrahepatic disease at the time of first presentation. Patients with locoregional lymph node disease or with small (≤ 1 cm) extrahepatic lesions that are too small to characterize or biopsy are eligible.
  • Second primary malignancy, except for adequately treated non-melanoma skin cancer, or other malignancy treated at least 3 years previously without evidence of recurrence or with a life expectancy longer than 5 years.
  • Known homozygous dihydropyrimidine dehydrogenase (DPYD) deficiency
  • Prior hepatic radiation, ablation, or resection for iCCA.
  • Clinical evidence of portal hypertension (ascites, gastroesophageal varices, or portal vein thrombosis). Some postoperative ascites is allowed.
  • (Partial) portal vein thrombosis in future liver remnant.
  • Pregnant or lactating women.
  • History of psychiatric disability judged by the investigator to be clinically significant, precluding informed consent or interfering with compliance for HAIP chemotherapy.
  • Serious concomitant systemic disorders that would compromise the safety of the patient or his/her ability to complete the study, at the discretion of the investigator.
  • Organ allografts requiring immunosuppressive therapy.
  • Serious infections (uncontrolled or requiring treatment).
  • Participation in another interventional study for iCCA with survival as outcome.
  • Participation in another prospective study with an interventional medical product.
  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Surgery + chemo pump (Hepatic Arterial Infusion Pump chemotherapy)

Surgery + chemo pump

Participants in this arm will receive in addition to standard care (surgery) a chemo pump. This pump will provide participants with 4 cycles of treatment with chemotherapy (Floxuridin), each lasting 4 weeks. Total treatment with chemotherapy will last 16 weeks (approx. 4 months)

Outros nomes:
  • Haip
  • Haic com floxuridina
  • Quimioterapia da bomba

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Two-year hepatic recurrence free survival (hRFS)
Prazo: From pump implantation until 2 years after that surgery

The percentage of patients who do not have return of disease in the liver two years after surgery. The time frame is defined as the period between pump implantation and return of disease in the liver. A recurrence is defined as a biopsy-proven recurrent lesion or radiological evidence with cross-sectional imaging in combination with an elevated CA19.9 or CEA level in the blood samples.

From pump implantation until 2 years after that surgery

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Overall recurrence free survival (RFS)
Prazo: From pump implantation until the earliest return of disease in the body during the study (up to 5 years after inclusion)

The percentage of patients who do not have return of disease in the given time frame. A recurrence is defined as a biopsy-proven recurrent lesion or radiological evidence with cross-sectional imaging in combination with an elevated CA19.9 or CEA level in the blood samples.

From pump implantation until the earliest return of disease in the body during the study (up to 5 years after inclusion)
Overall survival (OS)
Prazo: From pump implantation until death or lost to follow-up during the study (up to 5 years after inclusion)

OS is defined as the interval between pump implantation and the date of death (by any cause) or date of last follow-up

From pump implantation until death or lost to follow-up during the study (up to 5 years after inclusion)
Post-operative complications
Prazo: From pump implantation until 90 days after surgery

All complications rated Clavien-Dindo grade 3 or higher are recorded for the first 90 days after surgery.

From pump implantation until 90 days after surgery
Chemotherapy related adverse events (AEs)
Prazo: From inclusion until 4 weeks after the end of treatment with chemotherapy

Chemotherapy related adverse events (AEs) will be collected if they are grade III or higher according to CTCAE version 5.0

From inclusion until 4 weeks after the end of treatment with chemotherapy
Proportion of patients started with HAIP chemotherapy
Prazo: From pump implantation until the first cycle of HAIP chemotherapy, on average between 4 and 16 weeks after implantation of the HAIP chemopump

The number of patients that could receive at least 1 cycle of HAIP chemotherapy with floxuridin

From pump implantation until the first cycle of HAIP chemotherapy, on average between 4 and 16 weeks after implantation of the HAIP chemopump
Quality of life: EORTC QLQ-30
Prazo: From inclusion until 5 years after surgery

After study inclusion and every 3 months (+/- 30 days) thereafter patients will be asked to complete the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). This validated instrument includes 30 items covering functional domains, symptom scales, and global health status. Scores range from 0 to 100, with higher scores on the global health and functional scales indicating better quality of life.

After 1 year of follow-up, the questionnaires will be taken annually until a maximum of 5 years.

From inclusion until 5 years after surgery
Quality of life: EQ-5D
Prazo: From inclusion until 5 years after surgery

After study inclusion and every 3 months (+/- 30 days) thereafter patients will be asked to complete the EuroQol 5-Dimension (EQ-5D) questionnaire, a standardized measure of health-related quality of life. The EQ-5D includes five dimensions-mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The resulting health state is converted into an index score ranging from 0 (equivalent to death) to 1 (perfect health), though negative scores are possible.

After 1 year of follow-up, the questionnaires will be taken annually until a maximum of 5 years.

From inclusion until 5 years after surgery
Cost-effectiveness
Prazo: From implantation of the chemo pump until 2 years after (=timeframe of the primary outcome)

An assessment of the cost-effectiveness of HAIP chemotherapy for patients with iCCA will be made

From implantation of the chemo pump until 2 years after (=timeframe of the primary outcome)
Predictive biomarkers in the blood for efficacy of HAIP chemotherapy
Prazo: From implantation of the chemo pump until 1 year after surgery or return of disease (whichever comes first)

A total of five additional blood samples will be collected. These samples will be collected:

  • On the day of surgery before the incision is made.
  • During surgery (directly from the hepatic vein).
  • Before the start of HAIP chemotherapy.
  • After the last cycle of HAIP chemotherapy.
  • At one year after surgery or at recurrence
From implantation of the chemo pump until 1 year after surgery or return of disease (whichever comes first)
Predictive biomarkers from liver tissue for efficacy of HAIP chemotherapy
Prazo: From resection until 25 years after (conform applicable laws)

Additionally, tumor tissue will be collected from the removed part of the liver during the surgery. These tissue samples will be stored for further research into biomarkers.

From resection until 25 years after (conform applicable laws)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Bas Groot Koerkamp, MD, PhD, Erasmus Medical Center

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

20 de novembro de 2024

Conclusão Primária (Estimado)

1 de setembro de 2028

Conclusão do estudo (Estimado)

1 de setembro de 2033

Datas de inscrição no estudo

Enviado pela primeira vez

5 de fevereiro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

14 de março de 2025

Primeira postagem (Real)

21 de março de 2025

Atualizações de registro de estudo

Última Atualização Postada (Real)

23 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

21 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Descrição do plano IPD

The decision on sharing IPD has not been made within the trial team. Once this decision is made, we will update this part.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

produto fabricado e exportado dos EUA

Sim

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever